Candriam Luxembourg S.C.A. cut its position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 6.7% during the second quarter, Holdings Channel reports. The fund owned 560,000 shares of the biopharmaceutical company’s stock after selling 40,000 shares during the period. Candriam Luxembourg S.C.A.’s holdings in Catalyst Pharmaceuticals were worth $1,546,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of the stock. Renaissance Technologies LLC bought a new stake in Catalyst Pharmaceuticals during the first quarter worth about $746,000. Knott David M bought a new stake in Catalyst Pharmaceuticals during the first quarter worth about $554,000. JPMorgan Chase & Co. bought a new stake in Catalyst Pharmaceuticals during the first quarter worth about $155,000. Oxford Asset Management raised its stake in Catalyst Pharmaceuticals by 138.1% in the first quarter. Oxford Asset Management now owns 58,940 shares of the biopharmaceutical company’s stock worth $115,000 after buying an additional 34,181 shares during the last quarter. Finally, Vanguard Group Inc. raised its stake in Catalyst Pharmaceuticals by 0.5% in the first quarter. Vanguard Group Inc. now owns 3,007,935 shares of the biopharmaceutical company’s stock worth $5,865,000 after buying an additional 15,600 shares during the last quarter. 29.79% of the stock is currently owned by hedge funds and other institutional investors.

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) opened at 2.72 on Friday. The firm has a 50-day moving average price of $2.88 and a 200 day moving average price of $1.98. The firm’s market capitalization is $228.22 million. Catalyst Pharmaceuticals, Inc. has a one year low of $0.74 and a one year high of $3.20.

Catalyst Pharmaceuticals (NASDAQ:CPRX) last issued its earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.01. Equities research analysts anticipate that Catalyst Pharmaceuticals, Inc. will post ($0.25) earnings per share for the current year.

WARNING: This piece was originally reported by Watch List News and is owned by of Watch List News. If you are reading this piece on another domain, it was illegally copied and reposted in violation of U.S. and international copyright & trademark law. The correct version of this piece can be viewed at https://www.watchlistnews.com/candriam-luxembourg-s-c-a-sells-40000-shares-of-catalyst-pharmaceuticals-inc-cprx/1476995.html.

A number of equities research analysts recently issued reports on CPRX shares. Zacks Investment Research raised Catalyst Pharmaceuticals from a “hold” rating to a “buy” rating and set a $2.50 target price on the stock in a research note on Monday, May 22nd. Piper Jaffray Companies set a $6.00 target price on Catalyst Pharmaceuticals and gave the company a “buy” rating in a research note on Monday, August 7th. Finally, Roth Capital set a $5.00 target price on Catalyst Pharmaceuticals and gave the company a “buy” rating in a research note on Thursday.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, formerly Catalyst Pharmaceutical Partners, Inc, is a development-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for people with rare debilitating diseases. The Company has three drugs in development: Firdapse, CPP-109 and CPP-115.

Want to see what other hedge funds are holding CPRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX).

Institutional Ownership by Quarter for Catalyst Pharmaceuticals (NASDAQ:CPRX)

Receive News & Ratings for Catalyst Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.